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Purpose: To assess the safety and efficacy of changing to the travoprost/timolol fixed 
  combination (TTFC) from other mono- or adjunctive therapies.
Patients and methods: A prospective, open-label, observational cohort of primary open-angle 
glaucoma and ocular hypertensive patients whose intraocular pressure (IOP) was uncontrolled 
on prior therapy or was not on target. Patients were changed from prior mono- or adjunctive 
treatment at Day 0 to TTFC dosed every evening and underwent active treatment efficacy and 
safety evaluations at Week 12.
Results: In 474/522 (91%) patients who completed this trial an IOP (mm Hg) of 21.9 ± 2.0 
on prior treatment was reduced by TTFC at Month 3: from all prior treatments 5.6 ± 2.6; from 
monotherapy 5.9 ± 2.3; from adjunctive treatments 4.5 ± 2.9; and from several of the most 
frequent individual treatments: timolol 5.7 ± 2.2; latanoprost 6.3 ± 2.6; and latanoprost/timolol 
fixed combination 4.4 ± 1.9. Ocular hyperemia was the most frequent adverse effect (n = 21, 4%). 
Both patients and physicians preferred TTFC compared to all prior and common individual 
treatments. The solicited symptom survey showed, following a modified Bonferroni correction 
(α/5), a reduced incidence with TTFC of ocular pain (P = 0.01) while the prior medicine had a 
lower incidence of burning on instillation (P , 0.001).
Conclusions: Changing patients from prior mono- or adjunctive therapy to TTFC can provide 
on average a further reduction in IOP while demonstrating a favorable safety profile and a high 
patient preference.
Keywords: travoprost/timolol fixed combination, primary open-angle glaucoma, ocular hyper-
tension, safety, efficacy, intraocular pressure
Introduction
Recently the travoprost 0.004%/timolol 0.5% fixed combination (DuoTrav, Alcon 
Laboratories, Inc., Fort Worth, TX, USA) gained commercial approval for once daily 
dosing in the European Union. Barneby and associates showed that patients treated 
with the travoprost/timolol fixed combination, dosed each morning, had a greater 
reduction of intraocular pressure from baseline than timolol (1.9 to 3.3 mm Hg) or 
travoprost (0.9 to 2.4 mm Hg, [dosed each evening]) monotherapy.1
An observational study, such as the design of the current trial, may provide additive 
findings to randomized controlled comparisons by assessing treatment effectiveness 
in routine clinical practice. Such designs have the potential advantage of analyzing 
larger, more diverse patient populations than randomized controlled trials. Obser-
vational studies might identify differences in effectiveness and safety among more 
therapeutic options.2,3
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The primary objective of this study was to assess the 
safety and efficacy of changing to travoprost/timolol fixed 
combination from other mono- or adjunctive (fixed or unfixed 
combinations) therapies.
Patients and methods
Patients
This study was a prospective, open-label, observational cohort 
in 19 clinical centers in Germany involving 22 investigators. 
Patients included were: aged at least 18 years; diagnosed 
with ocular hypertension, primary open-angle or pigment 
dispersion glaucoma in at least one eye (study eye); treated 
with either mono- or adjunctive therapy (in a fixed or unfixed 
combination) for a minimum of one week at Visit 1 (this time 
period was chosen because we believed few patients who 
needed further pressure reduction would gain much greater 
efficacy following a week or more of treatment that a physi-
cian would delay adding a second medicine); demonstrated 
a need for greater ocular hypotensive efficacy; the last dose 
of the previous medicine was instilled correctly so the patient 
was within the dosing cycle of their previous medication(s) at 
Visit 1; at Visit 1, had a pressure of between 19–35 mm Hg 
inclusive in at least one eye and #35 mm Hg in both eyes on 
monotherapy or between 19–32 mm Hg inclusive in at least 
one eye and #32 mm Hg in both eyes on adjunctive therapy; 
and had best-corrected visual acuity of 6/60 (20/200 Snellen, 
1.0 logMAR) or better in each eye.
Excluded patients had: a presence of other primary or 
secondary glaucomas not listed in the inclusion criterion; 
presence of a narrow angle by gonioscopy not treated suc-
cessfully by iridectomy; any abnormality preventing reliable 
applanation tonometry in study eye(s); corneal dystrophies; 
any opacity or patient uncooperativeness that restricted 
adequate examination of the ocular fundus or anterior cham-
ber of the study eye(s); concurrent infectious/noninfectious 
conjunctivitis, keratitis or uveitis in either eye; intraocular 
conventional surgery or laser surgery in study eye(s) less than 
3 months prior to Visit 1; risk of visual field or visual acu-
ity worsening as a consequence of participation in the trial; 
progressive retinal or optic nerve disease from any cause; 
women of childbearing potential not using reliable means of 
birth control; women who were pregnant or lactating; any 
clinically significant, serious, or severe medical or psychiatric 
condition; a condition which would present a special risk to 
the patient; participation in any other investigational study 
within 30 days prior to Visit 1; known   medical history of 
allergy, hypersensitivity or poor tolerance to any components 
of the medications to be used in this trial; use of systemic 
medications known to affect the intraocular pressure which 
have not been on a stable course for at least 7 days prior to 
Visit 1 or an anticipated change in the dosage during the 
course of the study; reactive airway disease; sinus bradycar-
dia (,50 beats per minute); second- or third-degree atrioven-
tricular block; overt cardiac failure; severe allergic rhinitis; 
unwillingness to risk the possibility of darkened irides or 
eyelash changes; a history of, or at risk for uveitis, cystoid 
macular edema or history of ocular herpes simplex.
Procedures
Patients first signed an Ethics Committee-approved Informed 
Consent before any trial procedures were performed. This trial 
(NCT00519753) was registered at http://www.clinicaltrials.
gov/. At each visit patients underwent Goldmann applanation 
tonometry and slit lamp biomicroscopy, and had Snellen visual 
acuity and adverse event assessments performed. Patients 
completed a symptom survey at Visits 1 and 3 and both patients 
and physicians provided a global preference response at Visit 
3. At the end of Visit 1, qualified patients had their previous 
glaucoma therapy discontinued and received a commercially 
available open-label bottle of the travoprost/timolol fixed com-
bination to be used once every evening in the study eye(s).
Patients returned at Week 4 for a safety visit (Visit 2). 
Visit 2 was scheduled at the same time (±1 hour) as Visit 1. 
Patients must have been taking travoprost/timolol fixed 
combination as prescribed or the visit was rescheduled. At 
this visit, patients received two additional bottles of the study 
medicine for use until the end of the study. Patients whose 
intraocular pressure was elevated over baseline (Visit 1), who 
were considered treatment failures to travoprost/timolol fixed 
combination, had an intolerable adverse event, or had been 
noncompliant to therapy, were discontinued from the trial.
Patients returned for the final visit at Week 12 (Visit 3) 
which was scheduled at the same time (±1 hour) as Visit 1. 
Patients must have been taking their travoprost/timolol fixed 
combination as prescribed or the visit was rescheduled. The 
patient’s participation in the trial was considered successful if 
they completed the study (not discontinued due to noncompli-
ance or an adverse event) and demonstrated a further reduction 
in intraocular pressure ($1 mm Hg) from Visit 1. Patients 
withdrawn from the trial for protocol violations or medication 
errors were not included in the Per Protocol analysis.
Data analysis
The data were analyzed by PRN Pharmaceutical Research 
Network, LLC. All data analyses were two-sided and an 
α-level of 0.05 was used to declare statistical significance. An Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
461
Changing to the travoprost/timolol maleate fixed combination
average eye, Per Protocol analysis was utilized. Internet- based 
electronic data capture was used for the trial.
The primary efficacy variable, the change in intraocular 
pressure between travoprost and the travoprost/timolol fixed 
combination based on Per Protocol dataset, was analyzed 
using a paired t-test within a one-way analysis of variance 
(ANOVA) test.4 A standard deviation of 2.8 mm Hg was 
assumed to determine the sample size calculation.5,6 This 
study provided an 80% power that a difference of 1.5 mm 
Hg could be excluded between the travoprost/timolol fixed 
combination and travoprost if at least 27 patients were 
  analyzed for this subgroup.
The secondary efficacy variables: the change of intraocular 
pressure for the travoprost/timolol fixed combination from 
other therapeutic regimens (individual or group comparisons)   
also was analyzed using a paired t-test within an ANOVA. 
Only prior therapies with 27 or more patients who changed 
to the travoprost/timolol fixed combination were analyzed 
individually. This helped ensure a normal distribution of 
patients as well as a similar statistical power as the primary 
efficacy variable. For the change in pressure for the study 
cohort as a whole (from any previous therapy) to travoprost/
timolol fixed combination, a one-way ANOVA was used.4 A 
paired t-test within an ANOVA test was also used to evaluate 
differences in the patient surveys and visual acuity between 
baseline (Visit 1) and Week 12 (Visit 3). As a result of multiple 
subgroup assessments (differing prior therapies), a modified 
Bonferroni correction (α/5) was used to adjust the P-value.7
Adverse events were analyzed with a McNemar’s test6 for 
intragroup analysis, and global preference by a χ2 or Fisher’s 
exact test4 between travoprost/timolol fixed combination and 
prior therapy, as well as the study cohort as a whole.
Results
Patients
Table 1 describes the disposition of the patients who enrolled 
in the study and Table 2 details patient characteristics.
intraocular pressure
Intraocular pressure findings are presented in Table 3. Sig-
nificant decreases in intraocular pressure were observed from 
prior treatment (Visit 1, Day 0) with the travoprost/timolol 
fixed combination on the last exam (Visit 3, Month 3), from 
all prior mono- and adjunctive treatments, and from prior 
individual treatments that were analyzable with   sufficient 
statistical power to be clinically meaningful, which included 
travoprost (primary efficacy variable), timolol, latanoprost, 
latanoprost/timolol fixed combination, brinzolamide. 
In   addition, there was a significant improvement after 
changing from bimatoprost, but not bimatoprost/timolol 
fixed combination (P , 0.001 and P = 0.696, respectively). 
Figure 1 shows the intraocular pressure decrease from base-
line (Visit 1),   irrespective of prior therapy. At each prior 
intraocular   pressure level, there was a further significant 
decrease in pressure after changing to travoprost/timolol 
fixed combination (P , 0.001).
safety
The most frequent adverse events are shown in Table 4. In 
total, there were 93 (18%) patients with at least one ocular 
or systemic adverse event on travoprost/timolol fixed com-
bination with hyperemia being most frequent (n = 37, 7%). 
There were 10 (2%) systemic adverse events with headache 
(n = 5, 1%) being most frequent.
Overall, 20 (4%) patients were discontinued for an adverse 
event. The most common adverse event resulting in a patient’s 
discontinuation of the study was hyperemia (n = 6, 1%). 
There were three serious adverse events in patients, while on 
the travoprost/timolol fixed combination including, kidney 
stones (n = 1), dizziness (n = 1) and a fractured arm (n = 1). 
None of these serious events were believed to be related to 
the study medicine by the investigator.
Product preference and treatment 
success
Table 5 shows the preference by both the patient and doctor 
for either the travoprost/timolol fixed combination or the prior 
prescribed product. Both patients and doctors preferred the 
travoprost/timolol fixed combination to all prior treatments, 
both mono- and adjunctive treatments, and from common 
prior individual treatments.
Table 1 relevant population information – intention-to-Treat   
population
Population parameter Patients Percent 
intention-to-Treat population 522 100
Per Protocol population 474 91
subjects withdrawn for clinical reasons 
(more than one reason possible)
28 5
  Adverse events 19 4
  Withdrew consent 6 1
  noncompliance 2 0.4
  Lack of efficacy 1 0.2
  Lost to followup 1 0.2
  Other reasons 4 1
subjects withdrawn for protocol deviations 20 14
  Date of visit out of time frame 19 4
  Comedication not allowed Per Protocol 1 0.2Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
462
Pfeiffer et al
Table 3 Intraocular pressure at each study visit (by prior treatment) – Per Protocol population mean [mm Hg (standard deviation)]
Treatment Patients Visit 1 Visit 2 Visit 3 V1–V3 P-value
All 474 21.9 (2.1) 16.5 (2.2) 16.3 (2.2) 5.6 (2.6) ,0.001
Monotherapy 352 22.0 (2.2) 16.4 (2.2) 16.1 (1.9) 5.9 (2.4) ,0.001
Combined therapy 122 21.5 (2.0) 16.9 (2.3) 17.0 (2.9) 4.5 (2.8) ,0.001
Travoprost 45 22.1 (2.7) 16.2 (2.6) 15.8 (2.4) 6.3 (2.5) ,0.001
Timolol 130 21.8 (2.0) 16.4 (2.1) 16.1 (1.8) 5.7 (2.3) ,0.001
Latanoprost 60 22.3 (2.4) 16.7 (2.2) 16.0 (2.0) 6.3 (2.8) ,0.001
LTFC 47 21.5 (1.9) 17.6 (2.1) 17.1 (2.1) 4.4 (1.7) ,0.001
Brinzolamide 30 22.7 (2.4) 15.7 (2.5) 16.2 (2.3) 6.5 (2.8) ,0.001
Bimatoprost 16 22.4 (2.1) 16.1 (2.2) 16.3 (1.9) 6.2 (3.1) ,0.001
BTFC 2 20.8 (2.5) 16.0 (7.1) 17.0 (12.73) 3.8 (10.3) 0.70
Notes: The last two analyses were done despite the low number of patients because of the perceived importance of the clinical comparison.
Abbreviations: LTFC, latanoprost/timolol fixed combination; BTFC, bimatoprost/timolol fixed combination.
Table 2 Patient characteristics – intention-to-Treat population
Characteristic Variable Patients Percent
gender Female 318 61
Male 204 39
race Caucasian 516 99
Black 4 1
Asian 1 0.2
hispanic 1 0.2
iris color Blue 248 48
Brown  155 30
green 49 9
Other 70 13
Age (years) #55 70 13
56–65 123 24
66–75 196 38
$76 133 26
glaucoma diagnoses POAg  471 90
Ocular hypertension 43 8
Pigmentary glaucoma  8 2
Prior ophthalmic medication (n $ 30) Timolol 149 29
Latanoprost 64 12
LTFC 51 10
Travoprost 51 10
Brinzolamide 33 6
Other 174 33
Past medical history (most common) Arterial hypertension 205 39
  Diabetes 101 19
Thyroid 49 9
Lipid disorder 28 5
Coronary artery disease 22 4
hematologic disorder 19 4
neurologic seizure disorder 18 3
Concomitant medication (most common) ACe inhibitor 112 22
Beta-blocker 74 14
hormone therapy 77 15
Antihyperglycemic 52 10
Diuretic 44 8
Abbreviations: POAG, primary open-angle glaucoma; LTFC, latanoprost/timolol fixed combination; ACE, angiotensin-converting enzyme.
Table 6 shows the results of the solicited symptom   survey. 
Following the modified Bonferroni correction, there was 
a reduced incidence of ocular pain with the travoprost/timolol 
fixed combination (P = 0.01) and a reduction in eyelid   crusting 
that was approaching significance (P = 0.08).   Additionally, the 
prior medicine had a lower incidence of burning on   instillation 
(P , 0.001) although no patients discontinued their participa-
tion in the study due to this complaint.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
463
Changing to the travoprost/timolol maleate fixed combination
−4.1
−4.3
−4.8
−5.8
−6.5 −6.7
−8.2
−9.6 −10.0
−9.0
−8.0
−7.0
−6.0
−5.0
−4.0
−3.0
−2.0
−1.0
0.0
I
O
P
 
r
e
d
u
c
t
i
o
n
 
(
m
m
 
H
g
)
19 � IOP < 20 20 � IOP < 21 21 � IOP < 22 22 � IOP < 23 23 � IOP < 24 24 � IOP < 25 25 � IOP < 26 IOP � 26
23%
26%
28%
28%
32%
36%
21%
21%
Figure 1 The intraocular pressure (IOP) decrease from baseline (Visit 1), irrespective of prior therapy, for the Per Protocol population.
Table 4 Ocular or systemic adverse events by prior therapy – Intention-to-Treat population patients (%) (.10 occurrences)
Adverse event  All Monotherapy Combined therapy Travoprost Timolol Latanoprost LTFC Brinzolamide
Patients 522 388 134 51 149 64 51 33
All 93 (18) 65 (17) 28 (21) 9 (18) 33 (22) 5 (8) 3 (6) 4 (12)
  Mild 43 (8) 26 (7) 17 (13) 3 (6) 14 (9) 1 (2) 2 (4) 3 (9)
  Moderate 35 (7) 27 (7) 8 (6) 4 (8) 15 (10) 3 (5) 1 (2) 0 (0)
  severe 15 (3) 12 (3) 3 (2) 2 (4) 4 (3) 1 (2) 0 (0) 1 (3)
hyperemia 37 (7) 23 (6) 14 (10) 1 (2) 10 (7) 1 (2) 0 (0) 2 (6)
Ocular itching 13 (3) 10 (3) 3 (2) 1 (2) 6 (4) 0 (0) 1 (2) 0 (0)
Abbreviation: LTFC, latanoprost/timolol fixed combination.
Of patients initiating treatment, 93% (n = 484) were 
considered a treatment success by the definition pro-
vided in the methods section. Of patients changed from 
    mono- and adjunctive therapy respectively, 94% (n = 364) 
and 90% (n = 121) were considered a success. From com-
mon individual therapies: travoprost, 90% (n = 46); timolol, 
93% (n = 138); latanoprost, 92% (n = 59); the latanoprost/
timolol fixed combination, 96% (n = 49); and brinzolamide, 
97% (n = 32) were considered a success. There was not a 
statistical difference in success among the above individually 
considered treatment groups (P = 0.68).
Discussion
The primary objective of this study was to assess the safety 
and efficacy of changing to travoprost/timolol fixed com-
bination from other mono- or adjunctive (fixed or unfixed 
combinations) therapies.
This study showed significant decreases in intraocular 
pressure after 3 months of chronic dosing with the   travoprost/
timolol fixed combination from all common prior treat-
ments analyzed as a group, both mono- and adjunctive 
treatments analyzed as a group, and from prior individual 
treatments that were analyzable with sufficient statistical Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Table 5 Patient and doctor’s opinion about TTFC – Per Protocol population
Treatment Patients Patient prefers TTFC Doctor prefers TTFC
Percent Lower 95% CI Upper 95% CI Percent Lower 95% CI Upper 95% CI
All 474 88 86 91 91 89 94
Monotherapy 352 88 85 92 93 90 95
Combined therapy 122 89 83 94 88 82 94
Travoprost 45 93 86 100 93 86 100
Timolol 130 85 79 92 91 86 96
Latanoprost 60 90 82 98 97 92 100
LTFC 47 85 75 96 83 72 94
Brinzolamide 30 90 77 100 93 84 100
Bimatoprost 16 75 51 99 88 69 100
BTFC 2 100 100 100 50 0 100
Abbreviations: CI, confidence interval; TTFC, travoprost/timolol fixed combination; LTFC, latanoprost/timolol fixed combination; BTFC, bimatoprost/timolol fixed 
combination.
power to be clinically meaningful, which included travoprost, 
timolol, latanoprost, latanoprost/timolol fixed combination 
and brinzolamide. The average decrease in pressure from all 
prior treatments was 5.6 mm Hg; the average reduction from 
all prior monotherapy and adjunctive therapy was 5.9 mm Hg 
and 4.5 mm Hg, respectively. Importantly, this significant 
decrease in intraocular pressure occurred from prior levels 
of pressure when the patient was already treated with ocular 
hypotensive therapy. In addition, there was a significant 
improvement after changing from bimatoprost, but not the 
bimatoprost/timolol fixed combination. However, only two 
patients were available in the latter group. The bimatoprost 
groups were analyzed because of the importance of this 
compound in the treatment of glaucoma. Furthermore, there 
was a significant decrease in pressure after changing to the 
travoprost/timolol fixed combination regardless of the pres-
sure on common prior therapy (19 to .26 mm Hg). This 
finding indicates the effectiveness of the travoprost/timolol 
fixed combination in further reducing intraocular pressure 
across a wide range of prior therapy.
One of the problems in analyzing data from a trial in 
which a prior therapy is changed to a switch therapy in an 
open-label fashion is that the switch therapy has an inherent 
advantage in intraocular pressure reduction. The reason for 
this is not known but may result from the ‘regression to the 
mean’ phenomenon.8 This occurs because even a treated 
intraocular pressure typically fluctuates within a certain 
range. Accordingly, if the intraocular pressure is measured 
by chance at the high end of its typical range, it may not have 
been a true worsening of the disease. Therefore, a physician 
may adjust a therapeutic regimen to decrease an intraocular 
pressure that appears too high. By the next clinic visit, if 
the intraocular pressure appears normalized, any change in 
therapy from the prior visit may only have appeared to have 
improved the pressure because it may have regressed towards 
its mean even on the previous therapeutic regimen.
Nevertheless, in this current trial, the extent of intraocular 
pressure reduction with the travoprost/timolol fixed combi-
nation from prior treatment was higher than expected. Prior 
studies with similar design (ie, an open-label fashion) have 
shown an average reduction of 3.6 mm Hg from adjunctive 
treatment and 3.4 mm Hg from monotherapy treatment, 
when switched to a fixed combination therapy.8-14 Nonethe-
less, because of the unmasked, nonrandomized design of the 
current study design, further research is required to confirm 
the results of this study.
Safety results showed that the travoprost/timolol fixed 
combination was well tolerated in the majority of cases. In the 
Intention-to-Treat population, 4% of patients discontinued 
due to an adverse event, most commonly hyperemia (1%). 
An ocular or systemic adverse event occurred in 18% of 
patients, with the most common being hyperemia in 7% 
of patients. Systemic side effects were few, with the most 
frequent being headache at an incidence rate of 1%.
In total, 93% of patients were considered successfully 
treated with the travoprost/timolol fixed combination. The 
preference results showed a clear choice by both doctors and 
patients for the travoprost/timolol fixed combination. The 
reason for the strong preference for the fixed combination was 
not available in the product preference questionnaire. The 
preference choice may have been influenced by the positive 
results of the study, which showed that the travoprost based 
fixed combination appeared to have efficacy advantages, with 
a favorable safety profile, in comparison to prior therapies. 
Unfortunately, the results of the solicited patient survey failed 
to provide further clarity on why patients generally preferred 
the travoprost/timolol fixed combination. The survey results 
demonstrated that the travoprost/timolol fixed combination Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
465
Changing to the travoprost/timolol maleate fixed combination
Table 6 Ocular symptoms summary – Per Protocol population patients (%)
Level Visit 1 Visit 3 P-value
have you had dry eyes or dryness  
around your eyes since your last visit?
none 438 (92) 458 (97) 0.03
Minimal 8 (2) 5 (1)
Mild 16 (3) 8 (2)
Moderate 11 (2) 2 (0.4)
severe 1 (0.2) 1 (0.2)
have you had pain in or around your eye  
when in the light since your last visit?
none 465 (98) 471 (99) 0.01
Minimal 3 (0.6) 0 (0)
Mild 1 (0.2) 3 (0.6)
Moderate 5 (1) 0 (0)
have your eyes teared more than 
normal since your last visit?
none 455 (96) 464 (98) 0.23
Minimal 3 (0.6) 3 (0.6)
Mild 8 (2) 5 (1)
Moderate 6 (1) 2 (0.4)
severe 2 (0.4) 0 (0)
Did your study eye drops sting or 
burn when you instilled them?
none 453 (96) 422 (89) ,0.001
Minimal 12 (3) 29 (6)
Mild 7 (2) 4 (0.8)
Moderate 2 (0.4) 19 (4)
have you had crusting around  
your eyes since your last visit?
none 458 (97) 467 (99) 0.08
Minimal 9 (2) 6 (1)
Mild 4 (0.8) 1 (0.2)
Moderate 3 (0.6) 0 (0)
have you had itching of your eyes, eyelids, or 
the area around your eyes since your last visit?
none 445 (94) 441 (93) 0.93
Minimal 15 (3) 14 (3)
Mild 8 (2) 11 (2)
Moderate 5 (1) 7 (2)
severe 1 (0.2) 1 (0.2)
since your last visit did you experience a sandy  
or gritty feeling after you instilled your study drops?
none 454 (96) 453 (96) 0.72
Minimal 7 (2) 10 (2)
Mild 9 (2%) 9 (2)
Moderate 3 (0.6) 2 (0.4)
severe 1 (0.2) 0 (0)
have you had a feeling or irritation in 
your eyes since your last visit?
none 460 (97) 454 (96) 0.53
Minimal 6 (1) 5 (1)
Mild 5 (1) 9 (2)
Moderate 3 (0.6) 5 (1)
severe 0 (0) 1 (0.2)
have you noticed redness in your study eye? none 458 (97) 439 (93) 0.03
Minimal 3 (0.6) 11 (2)
Mild 9 (2) 11 (2)
Moderate 4 (0.8) 12 (3)
severe 0 (0) 1 (0.2)
have other people commented  
about redness in your study eye?
none 461 (97) 444 (94) 0.07
Minimal 5 (1) 18 (2)
Mild 3 (0.6) 10 (2)
Moderate 5 (1) 11 (2)
severe 0 (0) 1 (0.2)
how easy is it for you to get your  
eye drops in your study eye?
Very difficult 2 (0.4) 4 (0.8) 0.36
Difficult 16 (3) 13 (3)
easy 335 (71) 355 (75)
Very easy 121 (26) 102 (22)
was associated with less ocular pain but also showed more 
burning and stinging with the fixed combination. There 
was a trend towards more patients, and their acquaintances, 
noticing more ocular redness on the travoprost/timolol fixed 
combination, but this was not significant after the Bonferroni 
correction for multiple comparisons.
The data generated from this study are clinically 
important because they indicate that when an ocular Clinical Ophthalmology
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  hypertensive or primary open-angle glaucoma patient, 
who was previously treated with one or two glaucoma 
agents, is in need of further intraocular pressure reduc-
tion, a physician can generally anticipate greater pressure 
reduction with a favorable safety profile, high patient 
preference and a low dropout rate, by changing to the 
travoprost/timolol fixed combination.
Conclusion
This study suggests that changing patients from prior 
mono- or adjunctive therapy to the travoprost/timolol 
fixed combination can provide, on average, a further 
reduction in intraocular pressure while demonstrating 
a favorable safety profile and a high patient preference 
rate.
This study did not evaluate changing patients to the tra-
voprost/timolol fixed combination in a masked, randomized, 
parallel comparative trial. Consequently our design may have 
produced potential bias in the results. In addition, this study 
did not explore the long-term clinical outcomes of using 
the travoprost/timolol fixed combination. Further research, 
with a more robust study design, is required to more fully 
understand the clinical profile of the travoprost/timolol fixed 
combination in treating primary open-angle glaucoma and 
ocular hypertension.
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